H R Büller1, J L Halperin, H Bounameaux, M Prins. Show Affiliations » 1. Academic Medical Centre, Amsterdam, The Netherlands. h.r.buller@amc.uva.nl
Abstract
Mesh： See more » Anticoagulants/standardsAnticoagulants/therapeutic useBiasCase ManagementClinical Trials, Phase III as Topic/methodsClinical Trials, Phase III as Topic/standardsCost-Benefit AnalysisDouble-Blind MethodFibrinolytic Agents/standardsFibrinolytic Agents/therapeutic useHeparin/therapeutic useHeparin, Low-Molecular-Weight/therapeutic useHumansPatient SelectionProfessional PracticeProthrombin Time/instrumentationQuality of LifeRandomized Controlled Trials as Topic/methodsRandomized Controlled Trials as Topic/standardsThrombophilia/drug therapyTreatment OutcomeVitamin K/antagonists & inhibitors
Substances： See more » AnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-WeightVitamin KHeparin
Year: 2007 PMID： 18034770 DOI： 10.1111/j.1538-7836.2007.02848.x
Source DB: PubMed Journal: J Thromb Haemost ISSN： 1538-7836 Impact factor: 5.824